<h4>Background</h4>There is inconsistent evidence if hemizygous <i>CDKN2A/B</i> deletion affects survival in <i>IDH</i>-mutated glioma, and clinical characteristics are rarely accounted for. This evidence concerns the gene CDKN2A and central nervous system cancer.